Avadel Completes Patient Enrollment in REVITALYZ Trial, Data Expected Q2 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2025
0mins
Source: Newsfilter
- Trial Enrollment Completion: Avadel Pharmaceuticals announced the completion of patient enrollment in the REVITALYZ trial, which evaluates LUMRYZ as a potential treatment for idiopathic hypersomnia, with data expected in Q2 2026, marking a significant advancement for the company in this area.
- Clinical Trial Design: REVITALYZ is a double-blind, placebo-controlled multicenter Phase 3 trial designed to assess the efficacy and safety of LUMRYZ, particularly its effects on reducing daytime sleepiness, which, if approved by the FDA, will provide new treatment options for patients.
- Market Demand: Idiopathic hypersomnia is a serious sleep disorder affecting approximately 40,000 diagnosed patients in the U.S., and the development of LUMRYZ aims to meet this unmet market need, potentially enhancing Avadel's market position in the biopharmaceutical sector if successfully launched.
- Strategic Implications: As the first once-at-bedtime sodium oxybate medication, LUMRYZ has already achieved success in narcolepsy patients, and gaining approval for idiopathic hypersomnia would further solidify Avadel's image as an innovator in pharmaceuticals and drive long-term growth for the company.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
